Navigation Links
Prolaris® test predicts mortality risk in prostate cancer biopsy study

SALT LAKE CITY, Utah, May 20, 2014 Myriad Genetics, Inc. (NASDAQ: MYGN) today presented new data from a clinical validation study of Prolaris at the 2014 American Urological Association (AUA) Annual Meeting in Orlando, Fla. The study is the largest validation study to date of any gene-based prognostic test in patients with prostate cancer who were diagnosed by needle biopsy. A key finding was that the Prolaris test accurately differentiated newly diagnosed patients who were likely to die from prostate cancer within 10 years from those with lower-risk disease, which should open the door to more appropriate clinical care for patients at all risk levels. Prolaris is a novel molecular diagnostic test that accurately predicts cancer-specific death and metastases in men with prostate cancer and is a much stronger indicator of clinical outcomes than Gleason score or PSA.

"The aggressiveness of newly diagnosed prostate cancer is variable and difficult to predict. What clinicians really need is a well-validated prognostic test that accurately predicts disease-specific mortality and can improve patient care," said Jack Cuzick, PhD., study investigator and head of the Centre for Cancer Prevention at Queen Mary University of London. "Currently, with standard clinical tools like Gleason Score or PSA, we can't adequately define prognosis. The Prolaris test provides useful new information and is highly prognostic for disease-specific death among men being conservatively treated."

In this study, the goal was to validate the Prolaris test score in 761 conservatively managed prostate cancer patients diagnosed by needle biopsy. The primary endpoint was prostate cancer death and the median follow-up time was 9.5 years. The results showed that for each one unit increase in the Prolaris score, patients had approximately double the risk of dying from prostate cancer (see table).

    Prolaris Predicts 10-Year Death Rates from Prostate Cancer
    Prolaris Test Score <0 0-1 1.1-2 >2
    Death Rate (%) 7 15 36 59

Data from this study also showed that the Prolaris test is more predictive of mortality than Gleason score, PSA, age, clinical stage or extent of disease individually and almost doubles the total predictive information when they are combined. This study provides additional significant independent validation of the prognostic value of the Prolaris score in conservatively managed patients. The Prolaris test has now been validated in nine cohorts and more than 6,000 patients.

Prolaris Outperforms Upgrading Practice

In the second study featured at AUA, 230 men who had pathologic Gleason Scores of either 3+4 or 4+3 were examined. The Prolaris test was performed on the samples and the rates of biochemical recurrence (BCR) were compared in each group. The results showed that there was no difference in BCR based on an assessment using Gleason Score alone. However, the Prolaris test significantly outperformed the current practice of upgrading to Gleason 3+4 or 4+3 in predicting which patients would experience biochemical recurrence after a radical prostatectomy. These results underscore that genomic tests must be correlated with meaningful oncologic endpoints, rather than endpoints like upgrading. This finding should lead to improved initial decisions on the most effective treatment for each patient based on his personal risk of disease progression.

"Prolaris has been extensively validated in thousands of patients and is the most studied molecular prognostic test for prostate cancer in history," said Michael Brawer, M.D., vice president of Medical Affairs at Myriad Genetics. "Prolaris is rapidly becoming the leading test to assess the aggressiveness of prostate cancer and to help physicians select the most appropriate clinical management for patients newly diagnosed with prostate cancer."

Prolaris Is Strongest Predictor of Metastatic Prostate Cancer

The third study presented at AUA evaluated the prognostic utility of the Prolaris score generated from needle biopsy in men treated with prostatectomy. Importantly, the results of this study found that the Prolaris test was the strongest predictor of metastatic disease compared to other tested clinical variables. Patients with a high Prolaris score have more than a six-fold higher risk of developing metastases compared to patients with a low score. These results confirm that Prolaris may be used at the time of disease diagnosis to better determine which patients are at highest risk and help select appropriate medical care based on their personal risk profiles.


Contact: Ronald Rogers
Myriad Genetics, Inc.

Related medicine news :

1. Negative iron balance predicts acute heart failure survival
2. Effects of alcohol in young binge drinkers predicts future alcoholism
3. Better sleep predicts longer survival time for women with advanced breast cancer
4. Individual brain activity predicts tendency to succumb to daily temptations
5. Model predicts blood glucose levels 30 minutes later
6. Analysis of calls to IBD clinic predicts emergency visits and hospitalizations, Pitt finds
7. Severity of spatial neglect after stroke predicts long-term mobility recovery in community
8. Study: Autophagy predicts which cancer cells live and die when faced with anti-cancer drugs
9. Blood test accurately diagnoses concussion and predicts long term cognitive disability
10. New method predicts time from Alzheimers onset to nursing home, death
11. White Paper Predicts Less Snow More Rain Worldwide in Middle Latitudes
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer ... physician colleagues, skilled nursing facility medical directors and other clinicians at various events ... Care." , "At many of these conferences we get to educate other physicians, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. ... ...
Breaking Medicine Technology: